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Purpose: Focal neurodegeneration of the optic nerve in Leber hereditary optic neuropathy (LHON) is primarily due to a
maternally inherited mitochondrial DNA mutation. However, the markedly reduced penetrance of LHON and segregation
pattern of visual failure within families implicates an interacting nuclear genetic locus modulating the phenotype. Folate
deficiency is known to cause bilateral optic neuropathy, and defects of folate metabolism have been associated with
nonarteritic ischemic optic neuropathy.
Methods: Methylenetetrahydrofolate reductase (MTHFR) catalyzes a critical step in folate metabolism, and genetic
variation in MTHFR has been associated with several late-onset neurodegenerative diseases.
Results: We therefore determined whether functional genetic variants in MTHFR could account for the reduced penetrance
in LHON by studying 414 LHON mtDNA mutation carriers. We found no evidence of association between visual failure
in LHON and MTHFR polymorphisms or the MTHFR haplotype.
Conclusions: Genetic variation in MTHFR does not provide an explanation for the variable phenotype in LHON.
Leber  hereditary  optic  neuropathy  (LHON;  OMIM
#535000)  is  a  common  cause  of  inherited  blindness  that
typically  presents  with  bilateral,  painless,  subacute  vision
failure in young adult males. Affected individuals develop
focal degeneration of the optic nerve and present clinically
with impaired color vision (dyschromatopsia), a dense visual
field defect (central or cecocentral scotoma), and abnormal
visual electrophysiology due to primary retinal ganglion cell
loss [1]. The diagnosis is usually confirmed by molecular
genetic analysis for one of three common mitochondrial DNA
(mtDNA)  mutations  which  all  affect  genes  coding  for
complex I subunits of the respiratory chain: m.3460G>A, m.
11778G>A, and m14484T>C. However, only a few patients
harboring  a  pathogenic  LHON  mtDNA  mutation  develop
visual failure [2,3]. Segregation analysis of LHON pedigrees
indicated a two-locus model: a mtDNA mutation as one locus
and a modulating X-chromosomal locus [4]. Although an
interacting X-chromosomal locus could explain the gender
bias in LHON, not all pedigrees with LHON show linkage to
the X-chromosome [5-7], and the segregation pattern in some
pedigrees  implicates  one  or  more  autosomal  loci  [8].
However, attempts to identify a nuclear modifying gene by
both genetic mapping and functional genomics have so far
failed to identify the interacting nuclear genes.
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Research Group, The Medical School, Framlington Place, Newcastle
upon Tyne, NE2 4HH, United Kingdom; Phone: +44 191 222 8334;
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Folate is a necessary component for cellular maintenance
and  growth,  especially  important  during  early  embryonic
development,  where  it  is  involved  in  DNA  synthesis.
Methylenetetrahydrofolate reductase (MTHFR) catalyzes the
conversion  of  5,10-methylenetetrahydrofolate  to  5-
methyltetrahydrofolate, a critical step in the remethylation of
homocysteine  (Hcy)  to  methionine.  Genetic  variants  in
MTHFR  are  associated  with  hyperhomocysteinemia  and
cardiovascular disease [9] and are also associated with neural
tube  defects  in  the  fetus  [10].  c.677C>T,  present  at
approximately 33%–37% heterozygously and roughly 10%
homozygously in Europeans, leads to a substitution of alanine
to valine (at position 222) in the catalytic domain of MTHFR,
and subsequent reduction in enzyme activity [11]. This effect
is  magnified  when  c.677C>T  is  found  as  a  compound
heterozygote with homozygous c.1298A>C [12,13].
Previous studies have shown a link between oxidative
stress and increased Hcy in neurodegenerative disorders [14,
15], with a pronounced increase in Hcy in homozygote c.
677C>T Alzheimer disease [16] and Parkinson disease [17].
Elevated levels of Hcy have been shown to cause endothelial
dysfunction by increasing oxidative stress or impairing nitric
oxide  metabolism  [18,19].  Increased  Hcy  was  shown  to
induce apoptotic death in retinal ganglion cells, hypothesized
as a cause of LHON [20], by overstimulation of the N-methyl-
D-aspartate receptors and caspase-3 activation [21].
Increased  Hcy,  but  not  the  c.677C>T  variation,  was
identified  as  a  risk  factor  in  nonarteritic  ischemic  optic
neuropathy and central retinal vein occlusion [22,23]. Folate
Molecular Vision 2009; 15:870-875 <http://www.molvis.org/molvis/v15/a90>
Received 9 January 2009 | Accepted 16 April 2009 | Published 1 May 2009
© 2009 Molecular Vision
870T
A
B
L
E
 
1
.
 
N
O
N
-
S
Y
N
O
N
Y
M
O
U
S
 
M
T
H
F
R
 
V
A
R
I
A
N
T
S
 
I
N
 
L
H
O
N
.
G
e
n
o
t
y
p
e
 
f
r
e
q
u
e
n
c
y
P
a
t
i
e
n
t
s
W
T
H
e
t
M
T
P
r
s
4
5
4
3
8
5
9
1
A
1
7
3
8
0
0
.
3
2
3
C
2
2
2
6
0
r
s
1
8
0
1
1
3
3
A
1
1
3
5
6
1
3
0
.
4
7
9
C
1
5
1
6
0
2
1
r
s
4
5
5
7
1
7
3
6
A
1
2
7
5
0
3
0
.
5
8
5
C
1
7
2
5
4
3
r
s
1
8
0
1
1
3
1
A
8
1
7
8
2
3
0
.
1
4
3
C
1
1
2
1
0
2
1
6
r
s
2
2
7
4
9
7
6
A
1
5
1
2
5
5
0
.
1
0
4
C
2
0
7
1
9
3
r
s
3
5
7
3
7
2
1
9
A
1
7
7
2
3
0
.
1
7
1
C
2
2
1
9
2
A
l
l
e
l
e
 
f
r
e
q
u
e
n
c
y
P
a
t
i
e
n
t
s
W
T
M
T
P
r
s
4
5
4
3
8
5
9
1
A
3
5
4
8
0
.
2
8
5
4
C
4
5
0
6
r
s
1
8
0
1
1
3
3
A
2
8
2
8
2
0
.
8
6
7
C
3
6
2
1
0
2
r
s
4
5
5
7
1
7
3
6
A
3
0
4
5
6
0
.
3
6
4
C
3
9
8
6
0
r
s
1
8
0
1
1
3
1
A
2
4
0
1
2
4
0
.
1
3
1
C
3
2
6
1
3
4
r
s
2
2
7
4
9
7
6
A
3
2
7
3
5
0
.
0
3
C
4
3
3
2
5
r
s
3
5
7
3
7
2
1
9
A
3
5
6
8
0
.
6
6
C
4
5
1
1
3
C
o
m
p
a
r
i
s
o
n
 
o
f
 
M
T
H
F
R
 
v
a
r
i
a
n
t
 
g
e
n
o
t
y
p
e
 
a
n
d
 
a
l
l
e
l
e
 
f
r
e
q
u
e
n
c
i
e
s
 
b
e
t
w
e
e
n
 
L
H
O
N
 
p
a
t
i
e
n
t
s
 
(
A
)
 
a
n
d
 
c
o
n
t
r
o
l
s
 
(
C
;
 
w
h
e
r
e
 
W
T
 
a
n
d
 
M
T
 
a
r
e
 
h
o
m
o
z
y
g
o
u
s
 
 
 
w
i
l
d
-
t
y
p
e
 
a
n
d
 
m
u
t
a
n
t
,
 
r
e
s
p
e
c
t
i
v
e
l
y
 
a
n
d
 
H
e
t
 
i
s
 
h
e
t
e
r
o
z
y
g
o
u
s
.
 
P
 
i
s
 
a
n
 
u
n
c
o
r
r
e
c
t
e
d
 
P
e
a
r
s
o
n
’
s
 
c
h
i
-
s
q
u
a
r
e
 
p
r
o
b
a
b
i
l
i
t
y
)
.
Molecular Vision 2009; 15:870-875 <http://www.molvis.org/molvis/v15/a90> © 2009 Molecular Vision
871deficiency is known to cause bilateral optic neuropathy [24,
25].  Evidence  is  accumulating  that  implicates  folate
metabolism in optic neuropathies, particularly those affecting
the retinal ganglion cell, making MTHFR a strong autosomal
candidate genetic modifier in LHON, despite not localizing to
the X chromosome and therefore less likely to contribute
directly to the gender bias in LHON.
METHODS
We  studied  12  common  nonsynonymous  MTHFR
(NM_005957.3)  single  nucleotide  polymorphisms  (SNPs):
(rs2066472,  rs45550133,  rs45438591,  rs45571736,
rs45496998,  rs45449298,  rs2274974,  rs45590836,
rs2274976,  rs35737219,  rs1801133,  and  rs1801131)  in  a
European cohort of 414 LHON mtDNA mutation carriers
(182 affected, 232 unaffected). All subjects were recruited
from two European centers with local ethical review board
approval in accordance with the declaration of Helsinki. 70%
of  the  attached  individuals  were  male,  and  41%  of  the
unaffected individuals were male, in keeping with the gender
bias that characterizes LHON. All were homoplasmic for m.
3460G>A,  m.11778G>A,  or  m14484T>C.  rs1801133
corresponds to c.677C>T, and rs1801131 corresponds to c.
1298A>C. The additional ten SNPs were selected using the
following criteria: 1) nonsynonymous substitutions predicted
to affect MTHFR function; and 2) present in control subjects
at >0.1% (dbSNP) [26].
The  clinical  phenotype  was  determined  by  a  local
ophthalmologist [1] and the genetic diagnosis was confirmed
in affected individuals by mtDNA direct sequencing of the
MTND genes or PCR-RFLP analysis. Control participants
(unaffected mutation carriers) had no visual symptoms and
were older (>30 years) than the median age of onset for LHON
(24  years).  The  frequency  of  sequence  variants  was
determined  in  European  controls  by  primer  extension  of
multiplex  polymerase  chain  reaction  products  with  the
detection of the allele-specific extension products by matrix-
associated  laser  desorption/ionization  time  of  flight
(MALDITOF;  Sequenom,  San  Diego,  CA)  mass
spectrometry.  Genotype  and  allelic  associations  were
compared using SPSS v15.0 using Fishers exact test. The p
values given are two-tailed. To correct for multiple testing
bias,  we  performed  permutation  testing  using  Haploview
4.0.  Statistical  power  calculation  is  available  at  DSS
research.
RESULTS
We analyzed SNP frequencies in 12 non-synonymous SNPs
in  a  large  LHON  cohort.  Six  of  the  SNPs  (rs2066472,
rs45550133,  rs45496998,  rs45449298,  rs2274974,  and
rs45590836) showed no variation and were removed from any
further analysis. When males and females were considered
together,  Fisher  exact  test  revealed  a  weak  association
between rs2274976 and LHON (Table 1, p=0.030). When
males  and  females  were  considered  separately  (Table  2),
rs35737219 was associated with visual failure in male LHON
patients (p=0.043), When different LHON mutations were
studied  separately,  we  observed  a  significant  association
between rs45571736 and both m.3460 G>A and m.14484T>C
(Table 3, p=0.018 and 0.028 respectively). However none of
these  associations  were  significant  after  correcting  for
multiple testing bias using permutation testing.
When combining complex SNPs into complex genotypes
we found no association to a compound genotype of c.677C>T
and c.1298A>C (rs1801133:rs1801131; Table 4). We also
performed  six  locus  haplotyping  analysis.  There  was  no
significant  difference  in  the  frequency  of  each  genotype
between affected and unaffected.
DISCUSSION
We found no statistically robust association between any of
the 12 functional MTHFR SNPs, individually or as complex
TABLE 2. GENDER SPECIFIC MTHFR VARIANTS IN LHON.
rs1801131
:rs1801133 Total A U P
AA:CC 129 50 79 0.137
AA:CT 54 24 30 1
AA:TT 12 7 5 0.381
CA:CC 109 48 61 1
CA:CT 52 26 26 0.372
CA:TT 19 4 15 0.056
CC:CC 26 15 11 0.157
CC:CT 10 6 4 0.345
CC:TT 3 2 1 0.584
Total 414 182 232
Comparison of c.677C>T and c.1298A>C (rs1801133:rs1801131) compound genotypes between LHON patients (A) and
controls (C). P is an uncorrected Pearson’s chi-square probability).
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873genotypes, and vision failure in LHON families, or when
affected individuals were compared to controls. It is intriguing
that  specific  SNPs  appeared  to  be  associated  with  vision
failure when considered in subgroup analyses separating the
different LHON mtDNA mutations and different genders, but
these associations did not stand up to the rigors of a correction
for multiple significance testing. We therefore interpreted our
findings  conservatively,  but  larger  studies  may  show  that
these  associations  are  pathophysiologically  relevant.
Although  we  cannot  exclude  the  possibility  that  MTHFR
contributes to the pathophysiology of LHON, our findings
indicate that the gene is unlikely to be the major nuclear
genetic  modifier  interacting  with  the  primary  mtDNA
mutations. Genes encoding other enzymes involved in folate
metabolism may be relevant, as could dietary intake of folate.
Biochemical and epidemiological studies would address these
issues. Further genetic studies on a genome-wide level are
required to define the nuclear-mitochondrial interaction in
LHON.
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